Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) ...

Four years after winning an FDA approval for Koselugo to treat children with the rare disorder neurofibromatosis type 1 (NF1) ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Merck KGaA said its cell-tumor treatment Pimicotinib met its primary endpoint in a late-stage trial. The German pharma company said Tuesday that its experimental drug showed significant improvement in ...

Daiichi showed the mechanism can work in TGCT years ago, publishing phase 3 data in 2018 and winning FDA approval for Turalio ...

Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

In a groundbreaking initiative, the National Diabetes Association Ghana has announced the distribution of 300 boxes of ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that Canada's Drug Agency (CDA) has ...

Summit Therapeutics may have a powerful new cancer therapy on its hands. Merck is milking its cash cow oncology drug and ...

Merck & Co. said Friday that Canada's Drug Agency recommended the company's Winrevair for reimbursement as a treatment for adults with pulmonary arterial hypertension. The agency recommended the ...